Pulmonary Artery Banding (PA Banding) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Pulmonary artery banding (PAB) is a palliative cardiac surgical procedure in which a constrictive band is placed around the main pulmonary artery (MPA) to limit excessive pulmonary blood flow (Qp) in infants with large left-to-right cardiac shunts or complex single-ventricle congenital heart defects (CHD). First described by Muller and Dammann in 1952, PAB remains an essential tool in the paediatric cardiac surgeon's armamentarium when the underlying anatomical defect cannot be safely corrected in the neonatal or early infant period.

The physiological rationale is straightforward: unrestricted large left-to-right shunts cause pulmonary over-circulation, leading to pulmonary hypertension, progressive pulmonary vascular obstructive disease (Eisenmenger physiology), heart failure, failure to thrive, and recurrent lower respiratory infections. Without intervention, irreversible pulmonary vascular changes may preclude future surgical repair. PAB reduces pulmonary blood flow by creating a fixed or adjustable obstruction at MPA level, protecting the pulmonary vasculature and allowing the infant to stabilise and grow before definitive repair.

The target haemodynamic effect is a distal pulmonary artery pressure of approximately one-third to one-half of systemic arterial pressure, reducing the pulmonary-to-systemic flow ratio (Qp:Qs) to approximately 1.5:1 or less. This is assessed intraoperatively using direct pressure measurement and pulse oximetry, and confirmed post-operatively by echocardiography. The procedure is performed via median sternotomy or left lateral thoracotomy, without cardiopulmonary bypass (off-pump), and is typically well-tolerated even in the smallest and most haemodynamically compromised infants.

PAB is applied across a spectrum of congenital heart defects characterised by excessive pulmonary blood flow or complex anatomy precluding primary repair:

• Large unrestrictive ventricular septal defect (VSD): VSDs with equilisation of right and left ventricular pressures, causing biventricular failure and pulmonary hypertension in early infancy. PAB is used when the infant is too small or unwell for primary VSD closure, or when multiple VSDs (Swiss cheese septum) make primary repair technically not feasible at initial presentation.
• Atrioventricular septal defect (AVSD / AV canal defect): Complete AVSD combines a primum ASD, inlet VSD, and common AV valve. Associated with trisomy 21 in 70% of cases. Large shunts at both atrial and ventricular levels; PAB protects the pulmonary vasculature while definitive repair (biventricular repair) is planned at 3–6 months of age.
• Complex single-ventricle congenital heart disease: Conditions including double inlet left ventricle (DILV), tricuspid atresia with non-restrictive VSD, and heterotaxy syndromes where only one ventricle can support systemic circulation; PAB is part of the staged Fontan palliation pathway (PAB at Stage I if required, Glenn at Stage II, Fontan completion at Stage III).
• Hypoplastic left heart syndrome (HLHS) — hybrid Stage I: In selected high-risk neonates with HLHS, bilateral PAB combined with catheter-based ductal stent insertion (the hybrid approach) defers the high-risk Norwood aortic arch reconstruction to a later stage (comprehensive Stage II at 4–6 months), aiming to reduce early neonatal mortality.
• Multiple VSDs (Swiss cheese septum): Individual surgical or device closure of multiple muscular VSDs is not always feasible in a sick neonate; PAB provides palliation until a definitive strategy can be implemented as the infant grows.
• Pulmonary atresia with VSD and MAPCAs: Where pulmonary artery recruitment and rehabilitation is planned, PAB to native pulmonary arteries may be used in conjunction with MAPCA unifocalisation strategies.

The decision to perform PAB rather than primary anatomical repair is made by the multidisciplinary paediatric cardiac team (cardiac surgeon, cardiologist, intensivist, anaesthetist) on the basis of multiple clinical factors:

• Body weight and prematurity: Infants weighing less than 3–4 kg carry significantly higher operative mortality for primary intracardiac repair on cardiopulmonary bypass. PAB, performed off-pump, is better tolerated in extremely small infants and allows weight gain before definitive surgery. Premature infants with haemodynamically significant CHD may undergo PAB as a bridge to term-corrected age.
• Haemodynamic compromise: Infants with intractable heart failure despite maximal medical therapy (diuretics, ACE inhibition, nasogastric feeding) who cannot wait for growth before intervention. Echocardiographic and clinical evidence of pulmonary over-circulation and biventricular failure are key eligibility criteria.
• Anatomical complexity: Multiple muscular VSDs, complex inlet anatomy, or associated extracardiac anomalies may make primary repair technically inadvisable at initial presentation, favouring a staged approach with PAB.
• HLHS hybrid eligibility: Neonates with HLHS and significant risk factors for classical Norwood mortality (very low birth weight, prematurity, severe tricuspid regurgitation, or poor RV function) may be considered for the hybrid approach. The cardiac team also evaluates coronary perfusion adequacy and inter-atrial communication restrictiveness, as the hybrid strategy requires adequate atrial-level mixing; a transcatheter inter-atrial communication dilation may be performed concurrently.
• Contraindications to PAB: Established severe pulmonary vascular obstructive disease (Eisenmenger physiology) — characterised by pulmonary artery pressure equalling or exceeding systemic pressure with elevated pulmonary vascular resistance — is a contraindication to PAB since further reduction in pulmonary blood flow may critically compromise oxygen delivery. Cardiac catheterisation with vasoreactivity testing is performed when pulmonary vascular resistance elevation is suspected.

Several approaches to PAB exist, with material and device choice tailored to the clinical situation:

• Classic (fixed) PAB: A strip of PTFE tape, silicone band, or polyester tape is placed around the MPA and secured with sutures to achieve the target distal PA pressure and oxygen saturation intraoperatively. Simple, reproducible, and widely performed. The limitation of a fixed band is that it becomes progressively tighter as the infant grows (relative to the growing MPA), which may cause over-restriction and cyanosis without re-operation to loosen the band.
• FloWatch adjustable PAB (EndoArt SA, Geneva): A fully implantable adjustable device consisting of a hydraulic constrictive loop around the MPA connected via a subcutaneous reservoir to a radio-frequency receiver. Band diameter can be non-invasively adjusted postoperatively by a handheld external controller, allowing tightening or loosening in response to the infant's growth and haemodynamic status without re-operation. Particularly valuable in growing infants and in centres with high volume of complex single-ventricle CHD where PAB duration before Stage II may be prolonged. Higher initial device cost but potentially lower cumulative procedural cost by eliminating adjustment re-operations.
• Hybrid Stage I for HLHS: Performed in the cardiac catheterisation laboratory/hybrid theatre rather than conventional cardiac operating room. Bilateral PAB is placed via a small median sternotomy; a ductal stent is simultaneously placed via catheter via the ductus arteriosus to maintain systemic perfusion. If the inter-atrial septum is restrictive, balloon atrial septostomy or stenting is performed. Avoids deep hypothermic circulatory arrest and aortic arch reconstruction in the neonatal period. Stage II (comprehensive Norwood-Glenn) is performed at 4–6 months.
• Surgical access: Median sternotomy is most commonly used, providing excellent MPA access. Left lateral thoracotomy is an alternative approach that avoids sternotomy and preserves the pericardial space, particularly useful when the patient may require a future Fontan-type reconstruction.
• Band material considerations: PTFE tape is the most common material — biologically inert, non-stretching, and easy to secure. Silicone bands are softer and may cause less PA trauma at the band site. Umbilical tape (historical) is now rarely used due to ingrowth complications.

PAB provides critical haemodynamic benefits that protect the infant's pulmonary vasculature and create the conditions for safe definitive repair:

• Prevention of irreversible pulmonary hypertension: The most important benefit. Unrestricted large left-to-right shunts cause progressive pulmonary vascular remodelling; if Eisenmenger physiology develops, the patient becomes inoperable for repair. PAB prevents this by reducing pulmonary blood flow and pressure before irreversible vascular changes occur.
• Haemodynamic stabilisation: Infants with large shunts often have severe heart failure, failure to thrive, and recurrent respiratory infections. PAB rapidly reduces pulmonary over-circulation, improving symptoms within days to weeks. Improved feeding and weight gain follow, enabling safe growth to the weight and age appropriate for definitive repair.
• Bridge to definitive repair: Allows interval growth from neonatal/early infant weight to 4–8 kg, substantially reducing the mortality risk of intracardiac surgery on cardiopulmonary bypass. Primary repair of VSD in a 2 kg neonate carries significantly higher mortality than the same repair at 5–6 kg.
• FloWatch advantages: Non-invasive haemodynamic optimisation without re-operation as the infant grows. Reduces cumulative anaesthetic exposure in infants requiring prolonged palliation before definitive repair.
• Hybrid HLHS benefit: Avoids the deep hypothermic circulatory arrest and complex neonatal aortic arch reconstruction of the classical Norwood procedure, potentially reducing early neurological injury and reducing neonatal surgical mortality in the highest-risk subgroup of HLHS patients. The comprehensive Stage II procedure (Norwood-Glenn) is then performed under more controlled conditions in an older, larger, more haemodynamically stable infant.
• Off-pump procedure: PAB avoids cardiopulmonary bypass and its associated complications (systemic inflammatory response, coagulopathy, neurological injury), making it safer in critically ill neonates than primary repair.

PAB is an effective palliative procedure but carries specific complications that must be understood and monitored:

• Band migration: The most clinically significant late complication. The band may migrate distally from its intended MPA position toward the pulmonary artery bifurcation or into the origin of a branch pulmonary artery (typically the left PA, which is more directly in line with the MPA). Migration causes branch PA stenosis that may require surgical relief, patch augmentation, or catheter-based balloon dilation/stenting at the time of or prior to definitive repair.
• Pulmonary artery distortion at band site: Chronic constriction causes a waist or hourglass deformity of the MPA at the band site. At the time of definitive repair, the band is removed and the constricted segment of MPA must be assessed — it may require transverse incision and patch augmentation with autologous pericardium or PTFE to achieve an adequate pulmonary outflow tract.
• Over-tightening (excessive restriction): If the band is placed too tightly (distal PA pressure <1/3 systemic, SpO2 <70% in biventricular patients), right ventricular pressure overload develops, potentially causing RV failure, right-to-left shunting, and severe cyanosis. Intraoperative pressure monitoring and experienced surgical judgement are essential. Over-tightening requires immediate band loosening.
• Under-tightening: Insufficient band tightness fails to adequately protect the pulmonary vasculature, allowing continued pulmonary over-circulation, persistent heart failure symptoms, and potential pulmonary vascular remodelling. Requires re-intervention (band tightening or replacement).
• Left PA origin stenosis: Particularly with proximally placed bands, the left PA origin may be inadvertently compromised, causing left-sided pulmonary blood flow reduction and left lung under-perfusion.
• General surgical risks: Mediastinitis, phrenic nerve injury (causing diaphragm paralysis and post-operative respiratory compromise), thoracic duct injury (chylothorax), arrhythmia, and post-operative bleeding. These risks are managed at experienced paediatric cardiac surgical centres with dedicated PICU support.

Close post-operative surveillance is essential following PAB to optimise haemodynamic targets and plan the timing of definitive repair:

• Echocardiographic monitoring: The cornerstone of PAB follow-up. Key parameters assessed include: PAB Doppler gradient (target: consistent with distal PA pressure ~1/3 systemic); RV systolic pressure (should not approach systemic pressure unless VSD is intentionally left open for single-ventricle physiology); biventricular function; atrioventricular valve regurgitation; and somatic growth relative to band tightness. Initial weekly echo post-PAB, reducing to monthly once stable.
• Oxygen saturation monitoring: Continuous SpO2 monitoring in hospital; home SpO2 monitoring for outpatient follow-up in appropriate families. Target saturations depend on the underlying anatomy: biventricular (VSD/AVSD): SpO2 >90%; single-ventricle (HLHS hybrid): SpO2 70–80% with stable mixed venous saturation.
• FloWatch device adjustment: Where used, band diameter adjustment is performed in the cardiac catheterisation or outpatient setting as the infant grows. The device team adjusts based on echocardiographic parameters and clinical haemodynamic targets. Adjustment sessions replace the need for surgical re-operation.
• Nutritional support: Cardiac infants often require nasogastric tube feeding or gastrostomy for adequate caloric intake. Regular dietetic review. Target weight gain of 20–30 g per day.
• Pre-repair cardiac catheterisation: Performed before definitive repair to assess pulmonary vascular resistance (particularly important if repair is delayed >6 months), coronary anatomy (in HLHS hybrid), and accurate anatomical delineation.
• Timing of definitive repair: VSD and AVSD closure: typically 3–6 months. Fontan pathway Stage II (Glenn): 3–6 months. HLHS hybrid Stage II: 4–6 months. Decision is made by the multidisciplinary team based on weight, haemodynamic stability, echo parameters, and surgical readiness.

The cost of PAB and the associated care pathway is significant and reflects the complexity of paediatric cardiac surgery and intensive care:

• NHS England: PAB for congenital heart disease is commissioned through NHS England's Specialised Commissioning for Congenital Heart Disease, performed at designated Level 1 (surgical) CHD centres. Full funding is provided for eligible patients; families bear no direct surgical cost.
• PICU stay (dominant cost factor): Post-PAB PICU care is typically 3–10 days depending on haemodynamic stability and ventilation requirements. In UK private settings, PICU costs dominate the total cost of care — often £2,000–5,000 per PICU day.
• FloWatch device cost: Higher initial device cost than standard fixed band materials. However, if FloWatch eliminates 2–3 band adjustment re-operations, the cumulative cost including each re-operative PICU stay may favour the adjustable device in high-risk single-ventricle patients requiring prolonged palliation.
• Total care pathway cost: The complete staged CHD repair pathway (PAB + definitive repair + possible complications) must be considered. In the UK private sector, the complete pathway including two or more cardiac operations and PICU stays can reach £50,000–150,000 or more depending on complexity.
• International options: Leading paediatric cardiac centres offering complex CHD surgery at internationally competitive costs include Narayana Health (Bengaluru, India), AIIMS (New Delhi), Amrita Institute, Apollo Children's Hospital (Chennai), and King Faisal Specialist Hospital (Riyadh). JCI-accredited CHD programmes in India offer complex paediatric cardiac surgery at 15–25% of equivalent UK or US private costs, with outcomes comparable for select procedures at high-volume centres.

The choice between PAB and alternative strategies is made by the multidisciplinary cardiac team based on anatomy, weight, and institutional expertise:

• Primary anatomical repair (no PAB): In infants ≥3–4 kg with simple single VSD, experienced paediatric cardiac centres increasingly perform primary repair in the first month of life, avoiding PAB entirely and reducing overall operative burden and anaesthetic exposure. Outcomes of primary repair in experienced centres are equivalent to or better than staged PAB-then-repair for straightforward defects.
• Transcatheter VSD device closure: Catheter-delivered device closure of selected muscular or perimembranous VSDs (Amplatzer Muscular VSD occluder, Amplatzer Membranous VSD occluder) avoids open cardiac surgery entirely. Suitable for haemodynamically significant VSDs in infants >5 kg with appropriate anatomy. Not feasible for inlet VSDs, multiple VSDs, or those with adjacent structures precluding device deployment.
• Medical management (temporary palliation): Diuretics (furosemide, spironolactone), ACE inhibitors (captopril), and optimised nasogastric feeding can improve heart failure symptoms and facilitate weight gain in some infants with moderately large shunts, allowing deferral of any cardiac intervention. Not a definitive treatment — does not address the underlying defect.
• Classical Norwood Stage I (for HLHS, alternative to hybrid): The standard surgical palliation for HLHS: single-stage neonatal aortic arch reconstruction, atrial septectomy, and creation of a systemic-to-pulmonary shunt (Blalock-Taussig-Thomas or Sano modification). Established procedure with well-characterised outcomes at experienced centres. The hybrid approach (bilateral PAB + ductal stent) is an alternative for the highest-risk neonates.
• Heart transplantation: For complex CHD anatomies deemed unsuitable for any form of repair or Fontan palliation. Listed in the neonatal period if PAB is not feasible and surgical anatomy is inoperable; waiting list mortality is a significant limitation.
• Comfort/palliative care: In cases where cardiac anatomy is considered incompatible with survival or where family wishes preclude surgical intervention, compassionate care with symptom management is an ethically valid pathway discussed with the family by the cardiac team and clinical ethics consultants.